欧洲药典8.0-凡例双语版

合集下载

弗拉菌素(EP8.0)欧洲药典各论

弗拉菌素(EP8.0)欧洲药典各论

EUROPEAN PHARMACOPOEIA 8.0FramycetinsulfateI.[(RS )-[(1SR )-2-methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphoryl]aceticacid,K.(2S ,4S )-4-cyclohexyl-1-(2,2-dimethyl-1-oxopropyl)pyrroli-dine-2-carboxylicacid,N.(2S ,4S )-4-cyclohexyl-1-[[(2S ,4S )-4-cyclohexyl-1-[[(R )-[(1S )-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidin-2-yl]-carbonyl]pyrrolidine-2-carboxylic acid.01/2008:0180FRAMYCETIN SULFATEFramycetinisulfasC 23H 46N 6O 13,x H 2SO 4M r 615(base)[4146-30-9]DEFINITIONSulfate of 2-deoxy-4-O -(2,6-diamino-2,6-dideoxy-α-D -glucopyranosyl)-5-O -[3-O -(2,6-diamino-2,6-dideoxy-β-L -idopyranosyl)-β-D -ribofuranosyl]-D -streptamine (neomycin B).Substance produced by the growth of selected strains of Streptomyces fradiae or Streptomyces decaris or obtained byany other means.Content :minimum of 630IU/mg (dried substance).CHARACTERSAppearance :white or yellowish-white powder,hygroscopic.Solubility :freely soluble in water,very slightly soluble inalcohol,practically insoluble in acetone.IDENTIFICATION A.Examine the chromatograms obtained in the test forrelated substances.Results :–the retention time of the principal peak in the chromatogram obtained with the test solution isapproximately the same as that of the principal peak in the chromatogram obtained with reference solution (a),–it complies with the limit given for impurity C.B.It gives reaction (a)of sulfates (2.3.1).TESTSpH (2.2.3):6.0to 7.0.Dissolve 0.1g in carbon dioxide-free water R and dilute to 10mL with the same solvent.Specific optical rotation (2.2.7):+52.5to +55.5(dried substance).Dissolve 1.00g in water R and dilute to 10.0mL with the samesolvent Related substances .Liquid chromatography (2.2.29).Test solution .Dissolve 25.0mg of the substance to beexamined in the mobile phase and dilute to 50.0mL with the mobile phase.Reference solution (a).Dissolve the contents of a vial offramycetin sulfate CRS in the mobile phase and dilute with the mobile phase to obtain a solution containing 0.5mg/mL.Reference solution (b).Dilute 3.0mL of reference solution (a)to 100.0mL with the mobile phase.Reference solution (c).Dilute 1.0mL of reference solution (a)to 100.0mL with the mobile phase.Reference solution (d).Dissolve the contents of a vial of neamine CRS (corresponding to 0.5mg)in the mobile phase and dilute to 100.0mL with the mobile phase.Reference solution (e).Dissolve 10mg of neomycin sulfate CRS in the mobile phase and dilute to 100.0mL with the mobile phase.Column :–size :l =0.25m,Ø=4.6mm,–stationary phase :base-deactivated octadecylsilyl silica gel for chromatography R (5μm),–temperature :25°C.Mobile phase :mix 20.0mL of trifluoroacetic acid R ,6.0mL of carbonate-free sodium hydroxide solution R and 500mL of water R ,allow to equilibrate,dilute to 1000mL with water R and degas.Flow rate :0.7mL/min.Post-column solution :carbonate-free sodium hydroxidesolution R diluted 1in 25previously degassed,which is added pulse-less to the column effluent using a 375μL polymeric mixing coil.Flow rate :0.5mL/min.Detection :pulsed amperometric detector with a gold workingelectrode,a silver-silver chloride reference electrode and a stainless steel auxiliary electrode which is the cell body,held atrespectively 0.00V detection,+0.80V oxidation and −0.60Vreduction potentials,with pulse durations according to theinstrument used.Injection :10μL.Run time :1.5times the retention time of neomycin B.Relative retention with reference to neomycin B (retention time =about 10min):impurity A =about 0.65;impurity C =about 0.9;impurity G =about 1.1.System suitability :–resolution :minimum 2.0between the peaks due to impurity C and to neomycin B in the chromatogram obtained with reference solution (e);if necessary,adjust the volume of the carbonate-free sodium hydroxide solutionin the mobile phase,–signal-to-noise ratio :minimum 10for the principal peak in the chromatogram obtained with reference solution (c).General Notices (1)apply to all monographs and other texts2305Fructose EUROPEAN PHARMACOPOEIA8.0Limits :–impurity A :not more than the area of the principal peak in the chromatogram obtained with reference solution (d)and taking into account the declared content of neamine CRS (1.0per cent),–impurity C :not more than the area of the principal peak in the chromatogram obtained with reference solution (b)(3.0per cent),–total of other impurities :not more than the area of the principal peak in the chromatogram obtained with reference solution (b)(3.0per cent),–disregard limit :area of the principal peak in thechromatogram obtained with reference solution (c)(1.0per cent).Sulfate :27.0per cent to 31.0per cent (dried substance).Dissolve 0.250g in 100mL of water R and adjust the solution to pH 11using concentrated ammonia R .Add 10.0mLof 0.1M barium chloride and about 0.5mg of phthaleinpurple R .Titrate with 0.1M sodium edetate adding 50mL ofalcohol R when the colour of the solution begins to change andcontinuing the titration until the violet-blue colour disappears.1mL of 0.1M barium chloride is equivalent to 9.606mg of SO 4.Loss on drying (2.2.32):maximum 8.0per cent,determined on 1.000g by drying at 60°C over diphosphorus pentoxide R ata pressure not exceeding 0.7kPa for 3h.Sulfated ash (2.4.14):maximum 1.0per cent,determined on 1.0g.Sterility (2.6.1).If intended for introduction into bodycavities without a further appropriate sterilisation procedure,it complies with the test for sterility.Bacterial endotoxins (2.6.14,Method D ):less than 1.3IU/mgif intended for introduction into body cavities without afurther appropriate procedure for the removal of bacterial endotoxins.ASSAYCarry out the microbiological assay of antibiotics (2.7.2).Use framycetin sulfate CRS as the reference substance.STORAGEIn an airtight container,protected from light.If the substance is intended for introduction into body cavities,store in a sterile,tamper-proof container.IMPURITIESA.R1=H,R2=NH 2:2-deoxy-4-O -(2,6-diamino-2,6-dideoxy-α-D -glucopyranosyl)-D -streptamine (neamine or neomycin A-LP),B.R1=CO-CH 3,R2=NH 2:3-N -acetyl-2-deoxy-4-O -(2,6-diamino-2,6-dideoxy-α-D -glucopyranosyl)-D -streptamine (3-acetylneamine),D.R1=H,R2=OH:4-O -(2-amino-2-deoxy-α-D -glucopyranosyl)-2-deoxy-D -streptamine (paromamine or neomycinD), C.R1=CH 2-NH 2,R2=R3=H,R4=NH 2:2-deoxy-4-O -(2,6-diamino-2,6-dideoxy-α-D -glucopyranosyl)-5-O -[3-O -(2,6-diamino-2,6-dideoxy-α-D -glucopyranosyl)-β-D -ribofuranosyl]-D -streptamine (neomycin C),E.R1=R3=H,R2=CH 2-NH 2,R4=OH:4-O -(2-amino-2-deoxy-α-D -glucopyranosyl)-2-deoxy-5-O -[3-O -(2,6-diamino-2,6-dideoxy-β-L -idopyranosyl)-β-D -ribofuranosyl]-D -streptamine (paromomycin I orneomycin E),F.R1=CH 2-NH 2,R2=R3=H,R4=OH:4-O -(2-amino-2-deoxy-α-D -glucopyranosyl)-2-deoxy-5-O -[3-O -(2,6-diamino-2,6-dideoxy-α-D -glucopyranosyl)-β-D -ribofuranosyl]-D -streptamine (paromomycin II or neomycin F),G.R1=H,R2=CH 2-NH 2,R3=CO-CH 3,R4=NH 2:3-N -acetyl-2-deoxy-4-O -(2,6-diamino-2,6-dideoxy-α-D -glucopyranosyl)-5-O -[3-O -(2,6-diamino-2,6-dideoxy-β-L -idopyranosyl)-β-D -ribofuranosyl]-D -streptamine(neomycin B-LP).01/2008:0188corrected 6.0FRUCTOSEFructosum C 6H 12O 6M r 180.2[57-48-7]DEFINITIOND -arabino -Hex-2-ulopyranose.The substance described in this monograph is not necessarily suitable for parenteral administration.CHARACTERSAppearance :white or almost white,crystalline powder.It has a very sweet taste.Solubility :very soluble in water,soluble in ethanol (96per cent).IDENTIFICATIONA.Thin-layer chromatography (2.2.27).Solvent mixture :water R ,methanol R (2:3V/V ).Test solution .Dissolve 10mg of the substance to beexamined in the solvent mixture and dilute to 20mL with the solvent mixture.Reference solution (a).Dissolve 10mg of fructose CRS in the solvent mixture and dilute to 20mL with the solvent mixture.Reference solution (b).Dissolve 10mg each of fructose CRS ,glucose CRS ,lactose CRS and sucrose CRS in the solvent mixture and dilute to 20mL with the solvent mixture.Plate :TLC silica gel G plate R .2306See the information section on general monographs (cover pages)。

纯化水英汉对照-欧洲药典8.0

纯化水英汉对照-欧洲药典8.0

WATER,PURIFIED纯化水H2O M r18.12 DEFINITIONWater for the preparation of medicines other than those that are required to be both sterile and apyrogenic,unless otherwise justified and authorized.定义制药用水不同于其它用水,要求它是无菌的、无热源的,除非另有调整或授权。

Purified water in bulk散装纯化水PRODUCTIONPurified water in bulk is prepared by distillation,by ion exchange,by reverse osmosis or by any other suitable method from water that complies with the regulations on water intended for human consumption laid down by the competent authority.Purified water in bulk is stored and distributed in conditions designed to prevent growth of micro-organisms and to avoid any other contamination.生产:散装纯化水是经合格的当局规定的适宜人类使用的水经蒸馏、离子交换、反渗透膜或其他任何适合的方法制备。

散装纯化水存储和分配于可防止微生物生长和可避免其他任何污染的条件下。

Microbiological monitoring During production and subsequent storage, appropriate measures are taken to ensure that the microbial count is adequately controlled and monitored.Appropriate alert and action levels are set so as to detect adverse trends.Under normal conditions,an appropriate action level is a microbial count of100CFU/mL,determined by filtration through a membrane with a nominal pore size not greater than0.45μm,using R2A agar and incubating at30-35°C for not less than5days.The size of the sample is to be chosen in relation to the expected result.微生物监测在生产和其后的存储过程中,采取适当的方式以确保水的微生物数受到足够的控制和监测。

欧洲药典8.0 buffer solutions

欧洲药典8.0 buffer solutions

4.1.3.Buffer solutions EUROPEAN PHARMACOPOEIA8.0Sulfite standard solution (1.5ppm SO 2).5002900.Dissolve sodium metabisulfite R equivalent to 0.152g of Na 2S 2O 5in water R and dilute to 100.0mL with the same solvent.Dilute 5.0mL of this solution to 100.0mL with water R .To 3.0mL of the resulting solution,add 4.0mL of 0.1M sodium hydroxide and dilute to 100.0mL with water R .Thallium standard solution (10ppm Tl).5003000.Dissolve thallous sulfate R equivalent to 0.1235g of Tl 2SO 4in a 9g/L solution of sodium chloride R and dilute to 1000.0mL with the same solution.Dilute 10.0mL of the solution to 100.0mL with the 9g/L solution of sodium chloride R .Tin liposoluble standard solution (1000ppm Sn).5005000.A tin (metal)organic compound in an oil.Tin standard solution (5ppm Sn).5003100.Dissolve tin R equivalent to 0.500g of Sn in a mixture of 5mL of water R and 25mL of hydrochloric acid R and dilute to1000.0mL with water R .Dilute the solution to 100times itsvolume with a 2.5per cent V/V solution of hydrochloric acid R immediately before use.Tin standard solution (0.1ppm Sn).5003101.Immediately before use,dilute tin standard solution (5ppmSn)R to 50times its volume with water R .Titanium standard solution (100ppm Ti).5003200.Dissolve 100.0mg of titanium R in 100mL of hydrochloricacid R diluted to 150mL with water R ,heating if necessary.Allow to cool and dilute to 1000mL with water R .Vanadium standard solution (1g/L V).5003300.Dissolve in water R ammonium vanadate R equivalent to0.230g of NH 4VO 3and dilute to 100.0mL with the samesolvent.Zinc standard solution (5mg/mL Zn).5003400.Dissolve 3.15g of zinc oxide R in 15mL of hydrochloric acid Rand dilute to 500.0mL with water R .Zinc standard solution (100ppm Zn).5003401.Immediately before use,dilute with water R to 10times its volume a solution containing zinc sulfate R equivalent to0.440g of ZnSO 4,7H 2O and 1mL of acetic acid R in 100.0mL.Zinc standard solution (10ppm Zn).5003402.Immediately before use,dilute zinc standard solution (100ppm Zn)R to 10times its volume with water R .Zinc standard solution (5ppm Zn).5003403.Immediately before use,dilute zinc standard solution (100ppm Zn)R to 20times its volume with water R .Zirconium standard solution (1g/L Zr).5003500.Dissolve zirconyl nitrate R equivalent to 0.293g ofZrO(NO 3)2,2H 2O in a mixture of 2volumes of hydrochloric acid R and 8volumes of water R and dilute to 100.0mL with the same mixture of solvents.01/2014:401034.1.3.BUFFER SOLUTIONSBuffered acetone solution.4000100.Dissolve 8.15g of sodium acetate R and 42g of sodium chloride R in water R ,add 68mL of 0.1M hydrochloric acid and 150mL of acetone R and dilute to 500mL with water R .Buffer solution pH 2.0.4000200.Dissolve 6.57g of potassium chloride R in water R and add 119.0mL of 0.1M hydrochloric acid .Dilute to 1000.0mL with water R .Phosphate buffer solution pH 2.0.4007900.Dissolve 8.95g of disodium hydrogen phosphate R and 3.40g of potassium dihydrogen phosphate R in water R and dilute to 1000.0mL with the same solvent.If necessary adjust the pH with phosphoric acid R .Sulfate buffer solution pH 2.0.4008900.Dissolve 132.1g of ammonium sulfate R in water R and dilute to 500.0mL with the same solvent (Solution A).Carefully and with constant cooling stir 14mL of sulfuric acid R into about 400mL of water R ;allow to cool and dilute to 500.0mL with water R (Solution B).Mix equal volumes of solutions A and B.Adjust the pH if necessary.Buffer solution pH 2.2.4010500.Mix 6.7mL of phosphoric acid R with 55.0mL of a 40g/Lsolution of sodium hydroxide R and dilute to 1000.0mL with water R .Buffer solution pH 2.5.4000300.Dissolve 100g of potassium dihydrogen phosphate R in 800mL of water R ;adjust to pH 2.5with hydrochloric acid R anddilute to 1000.0mL with water R .Buffer solution pH 2.5R1.4000400.To 4.9g of dilute phosphoric acid R add 250mL of water R .Adjust the pH with dilute sodium hydroxide solution R anddilute to 500.0mL with water R .0.2M Phosphate buffer solution pH 2.5.4014100.Dissolve 27.2g of potassium dihydrogen phosphate R in about900mL of water R ,adjust to pH 2.5with phosphoric acid Rand dilute to 1.0L with water R .Phosphate buffer solution pH 2.8.4010600.Dissolve 7.8g of sodium dihydrogen phosphate R in 900mL ofwater R ,adjust to pH 2.8with phosphoric acid R and dilute to1000mL with the same solvent.Buffer solution pH 3.0.4008000.Dissolve 21.0g of citric acid R in 200mL of 1M sodiumhydroxide and dilute to 1000mL with water R .Dilute 40.3mL of this solution to 100.0mL with 0.1M hydrochloric acid .0.25M Citrate buffer solution pH 3.0.4012600.Dissolve 5.3g of citric acid R in 80mL of water R .Adjust thepH with 1M sodium hydroxide and dilute to 100.0mL with water R .0.1M Phosphate buffer solution pH 3.0.4011500.Dissolve 12.0g of anhydrous sodium dihydrogen phosphate R in water R ,adjust the pH with dilute phosphoric acid R1and dilute to 1000mL with water R .Phosphate buffer solution pH 3.0.4000500.Mix 0.7mL of phosphoric acid R with 100mL of water R .Dilute to 900mL with the same solvent.Adjust to pH 3.0with strong sodium hydroxide solution R and dilute to 1000mL with water R .Phosphate buffer solution pH 3.0R1.4010000.Dissolve 3.40g of potassium dihydrogen phosphate R in900mL of water R .Adjust to pH 3.0with phosphoric acid R and dilute to 1000.0mL with water R .Phosphate buffer solution pH 3.2.4008100.To 900mL of a 4g/L solution of sodium dihydrogenphosphate R ,add 100mL of a 2.5g/L solution of phosphoric acid R .Adjust the pH if necessary.Phosphate buffer solution pH 3.2R1.4008500.Adjust a 35.8g/L solution of disodium hydrogen phosphate R to pH 3.2with dilute phosphoric acid R .Dilute 100.0mL of the solution to 2000.0mL with water R .EUROPEAN PHARMACOPOEIA 8.0 4.1.3.BuffersolutionsBuffer solution pH 3.5.4000600.Dissolve 25.0g of ammonium acetate R in 25mL of water R and add 38.0mL of hydrochloric acid R1.Adjust the pH if necessary with dilute hydrochloric acid R or dilute ammonia R1.Dilute to 100.0mL with water R .Phosphate buffer solution pH 3.5.4000700.Dissolve 68.0g of potassium dihydrogen phosphate R in water R and dilute to 1000.0mL with the same solvent.Adjustthe pH with phosphoric acid R .Buffer solution pH 3.6.4000800.To 250.0mL of 0.2M potassium hydrogen phthalate R add11.94mL of 0.2M hydrochloric acid .Dilute to 1000.0mLwith water R .Buffer solution pH 3.7.4000900.To 15.0mL of acetic acid R add 60mL of ethanol (96percent)R and 20mL of water R .Adjust to pH 3.7by the addition of ammonia R .Dilute to 100.0mL with water R .Buffered copper sulfate solution pH 4.0.4001000.Dissolve 0.25g of copper sulfate R and 4.5g of ammonium acetate R in dilute acetic acid R and dilute to 100.0mL with the same solvent.0.1M Sodium acetate buffer solution pH 4.0.4013800.Dissolve 822mg of sodium acetate R in 100mL of water R (solution A).Dilute 1.44mL of glacial acetic acid R in 250mL of water R (solution B).Titrate 100mL of solution B using about 20mL of solution A.Acetate buffer solution pH 4.4.4001100.Dissolve 136g of sodium acetate R and 77g of ammonium acetate R in water R and dilute to 1000.0mL with the same solvent;add 250.0mL of glacial acetic acid R and mix.Phthalate buffer solution pH 4.4.4001200.Dissolve 2.042g of potassium hydrogen phthalate R in 50mL of water R ,add 7.5mL of 0.2M sodium hydroxide and dilute to 200.0mL with water R .Acetate buffer solution pH 4.5.4012500.Dissolve 77.1g of ammonium acetate R in water R .Add 70mL of glacial acetic acid R and dilute to 1000.0mL with water R .0.5M Ammonium acetate buffer solution pH 4.5.4014200.Mix 14.3mL of glacial acetic acid R and 470mL of water Rand adjust to pH 4.5with concentrated ammonia R .Dilute to 500.0mL with water R .0.05M Phosphate buffer solution pH 4.5.4009000.Dissolve 6.80g of potassium dihydrogen phosphate R in1000.0mL of water R .The pH of the solution is 4.5.Sodium acetate buffer solution pH 4.5.4010100.Dissolve 63g of anhydrous sodium acetate R in water R ,add 90mL acetic acid R and adjust to pH 4.5,and dilute to1000mL with water R .Acetate buffer solution pH 4.6.4001400.Dissolve 5.4g of sodium acetate R in 50mL of water R ,add2.4g of glacial acetic acid R and dilute to 100.0mL withwater R .Adjust the pH if necessary.Succinate buffer solution pH 4.6.4001500.Disssolve 11.8g of succinic acid R in a mixture of 600mL ofwater R and 82mL of 1M sodium hydroxide and dilute to1000.0mL with water R .Acetate buffer solution pH 4.7.4001600.Dissolve 136.1g of sodium acetate R in 500mL of water R .Mix 250mL of this solution with 250mL of dilute acetic acid R .Shake twice with a freshly prepared,filtered,0.1g/L solution of dithizone R in chloroform R .Shake with carbon tetrachloride R until the extract is colourless.Filter the aqueous layer to remove traces of carbon tetrachloride.Acetate buffer solution pH 4.7R1.4013600.Dissolve 136.1g of sodium acetate R in 500mL of water R .Mix 250mL of this solution with 250mL of dilute acetic acid R .Acetate buffer solution pH 5.0.4009100.To 120mL of a 6g/L solution of glacial acetic acid R add 100mL of 0.1M potassium hydroxide and about 250mL ofwater R .Mix.Adjust the pH to 5.0with a 6g/L solution ofacetic acid R or with 0.1M potassium hydroxide and dilute to 1000.0mL with water R .Citrate buffer solution pH 5.0.4010700.Prepare a solution containing 20.1g/L of citric acid R and 8.0g/L of sodium hydroxide R .Adjust the pH with dilute hydrochloric acid R .0.2M Deuterated sodium phosphate buffer solution pH 5.0.4013900.Dissolve 2.76g of sodium dihydrogen phosphate monohydrate R in 90mL of deuterium oxide R ,adjust the pH with a deuterated solution of phosphoric acid R or a deuterated 1M solution of sodium hydroxide R ,dilute to 100mL with deuterium oxide R and mix.Phosphate buffer solution pH 5.0.4011300.Dissolve 2.72g of potassium dihydrogen phosphate R in 800mL of water R .Adjust the pH with 1M potassium hydroxide and dilute to 1000mL with water R .Buffer solution pH 5.2.4001700.Dissolve 1.02g of potassium hydrogen phthalate R in 30.0mL of 0.1M sodium hydroxide .Dilute to 100.0mL with water R .0.067M Phosphate buffer solution pH 5.4.4012000.Mix appropriate volumes of a 23.99g/L solution of disodium hydrogen phosphate R with a 9.12g/L solution of sodium dihydrogen phosphate monohydrate R to obtain pH 5.4.Acetate-edetate buffer solution pH 5.5.4001900.Dissolve 250g of ammonium acetate R and 15g sodiumedetate R in 400mL of water R and add 125mL of glacial acetic acid R .Buffer solution pH 5.5.4001800.Dissolve 54.4g of sodium acetate R in 50mL of water R ,heating to 35°C if necessary.After cooling,slowly add 10mL of anhydrous acetic acid R .Shake and dilute to 100.0mL withwater R .Phosphate buffer solution pH 5.5.4002000.Dissolve 13.61g of potassium dihydrogen phosphate R inwater R and dilute to 1000.0mL with the same solvent(solution A).Dissolve 35.81g of disodium hydrogen phosphate R in water R and dilute to 1000.0mL with the same solvent (solution B).Mix 96.4mL of solution A and 3.6mL of solution B.Phosphate-citrate buffer solution pH 5.5.4008700.Mix 56.85mL of a 28.4g/L solution of anhydrous disodium hydrogen phosphate R and 43.15mL of a 21g/L solution of citric acid R .Phosphate buffer solution pH 5.6.4011200.Dissolve 0.908g of potassium dihydrogen phosphate R in water R and dilute to 100.0mL with the same solvent (solution A).Dissolve 1.161g of dipotassium hydrogenphosphate R in water R and dilute to 100.0mL with the same solvent (solution B).Mix 94.4mL of solution A and 5.6mL of solution B.If necessary,adjust to pH 5.6using solution A or solution B.4.1.3.Buffer solutions EUROPEAN PHARMACOPOEIA8.0Phosphate buffer solution pH5.8.4002100.Dissolve1.19g of disodium hydrogen phosphate dihydrate R and8.25g of potassium dihydrogen phosphate R in water R and dilute to1000.0mL with the same solvent.Acetate buffer solution pH6.0.4002200.Dissolve100g of ammonium acetate R in300mL of water R, add4.1mL of glacial acetic acid R,adjust the pH if necessary using ammonia R or acetic acid R and dilute to500.0mL with water R.Diethylammonium phosphate buffer solution pH6.0. 4002300.Dilute68mL of phosphoric acid R to500mL with water R. To25mL of this solution add450mL of water R and6mLof diethylamine R,adjust to pH6±0.05,if necessary,using diethylamine R or phosphoric acid R and dilute to500.0mL with water R.Phosphate buffer solution pH6.0.4002400.Mix63.2mL of a71.5g/L solution of disodium hydrogen phosphate R and36.8mL of a21g/L solution of citric acid R. Phosphate buffer solution pH6.0R1.4002500.Dissolve6.8g of sodium dihydrogen phosphate R in water R and dilute to1000.0mL with water R.Adjust the pH with strong sodium hydroxide solution R.Phosphate buffer solution pH6.0R2.4002600.To250.0mL of0.2M potassium dihydrogen phosphate R add 28.5mL of0.2M sodium hydroxide and dilute to1000.0mL with water R.Phosphate buffer solution pH6.4.4002800.Dissolve2.5g of disodium hydrogen phosphate R,2.5g of sodium dihydrogen phosphate R and8.2g of sodium chloride R in950mL of water R.Adjust the pH of the solution to6.4with 1M sodium hydroxide or1M hydrochloric acid,if necessary. Dilute to1000.0mL with water R.0.5M Phthalate buffer solution pH6.4.4009200. Dissolve100g of potassium hydrogen phthalate R in water R and dilute to1000.0mL with the same solvent.Adjust the pH if necessary,using strong sodium hydroxide solution R. Buffer solution pH6.5.4002900.Dissolve60.5g of disodium hydrogen phosphate R and46g of potassium dihydrogen phosphate R in water R.Add100mL of 0.02M sodium edetate and20mg of mercuric chloride R and dilute to1000.0mL with water R.Imidazole buffer solution pH6.5.4003000.Dissolve6.81g of imidazole R,1.23g of magnesium sulfate R and0.73g of calcium sulfate R in752mL of0.1M hydrochloric acid.Adjust the pH if necessary and dilute to1000.0mL with water R.0.1M phosphate buffer solution pH6.5.4010800. Dissolve13.80g of sodium dihydrogen phosphate monohydrate R in900mL of distilled water R.Adjust the pH using a400g/L solution of sodium hydroxide R.Dilute to 1000mL with distilled water R.Phosphate buffer solution pH6.5.4012800.Dissolve2.75g of sodium dihydrogen phosphate R and4.5g of sodium chloride R in500mL of water R.Adjust the pH with phosphate buffer solution pH8.5R.Buffer solution pH6.6.4003100.To250.0mL of0.2M potassium dihydrogen phosphate R add 89.0mL of0.2M sodium hydroxide.Dilute to1000.0mL with water R.0.1M Phosphate buffer solution pH6.7.4014300. Dissolve15.6g of sodium dihydrogen phosphate R in water R and dilute to1.0L with the same solvent.Dissolve17.8g of disodium hydrogen phosphate dihydrate R in water R and dilute to1.0L with the same solvent.Mix the solutions,check the pH and if necessary adjust to pH6.7.Phosphate buffered saline pH6.8.4003200.Dissolve1.0g of potassium dihydrogen phosphate R,2.0gof dipotassium hydrogen phosphate R and8.5g of sodium chloride R in900mL of water R,adjust the pH if necessary and dilute to1000.0mL with the same solvent. Phosphate buffer solution pH6.8.4003300.Mix77.3mL of a71.5g/L solution of disodium hydrogen phosphate R with22.7mL of a21g/L solution of citric acid R. Phosphate buffer solution pH6.8R1.4003400.To51.0mL of a27.2g/L solution of potassium dihydrogen phosphate R add49.0mL of a71.6g/L solution of disodium hydrogen phosphate R.Adjust the pH if necessary. Storage:at2°C to8°C.1M tris-hydrochloride buffer solution pH6.8.4009300. Dissolve60.6g of tris(hydroxymethyl)aminomethane R in 400mL of water R.Adjust the pH with hydrochloric acid R and dilute to500.0mL with water R.Buffer solution pH7.0.4003500.To1000mL of a solution containing18g/L of disodium hydrogen phosphate R and23g/L of sodium chloride R add sufficient(about280mL)of a solution containing7.8g/Lof sodium dihydrogen phosphate R and23g/L of sodium chloride R to adjust the pH.Dissolve in the solution sufficient sodium azide R to give a0.2g/L solution.Maleate buffer solution pH7.0.4003600.Dissolve10.0g of sodium chloride R,6.06g oftris(hydroxymethyl)aminomethane R and4.90g of maleic anhydride R in900mL of water R.Adjust the pH using a 170g/L solution of sodium hydroxide R.Dilute to1000.0mL with water R.Storage:at2°C to8°C;use within3days.0.025M Phosphate buffer solution pH7.0.4009400.Mix1volume of0.063M phosphate buffer solution pH7.0R with1.5volumes of water R.0.03M Phosphate buffer solution pH7.0.4010300. Dissolve5.2g of dipotassium hydrogen phosphate R in900mL of water for chromatography R.Adjust the solution to pH7.0±0.1using phosphoric acid R and dilute to1000mL with water for chromatography R.0.05M Phosphate buffer solution pH7.0.4012400.Mix34mL of water R and100mL of0.067M phosphate buffer solution pH7.0R.0.063M Phosphate buffer solution pH7.0.4009500. Dissolve5.18g of anhydrous disodium hydrogen phosphate R and3.65g of sodium dihydrogen phosphate monohydrate R in 950mL of water R and adjust the pH with phosphoric acid R; dilute to1000.0mL with water R.0.067M Phosphate buffer solution pH7.0.4003800. Dissolve0.908g of potassium dihydrogen phosphate Rin water R and dilute to100.0mL with the same solvent (solution A).Dissolve2.38g of disodium hydrogen phosphate R in water R and dilute to100.0mL with the same solvent (solution B).Mix38.9mL of solution A and61.1mL of solution B.Adjust the pH if necessary.EUROPEAN PHARMACOPOEIA 8.0 4.1.3.Buffersolutions0.1M Phosphate buffer solution pH 7.0.4008200.Dissolve 1.361g of potassium dihydrogen phosphate R in water R and dilute to 100.0mL with the same solvent.Adjust the pH using a 35g/L solution of disodium hydrogen phosphate R .Phosphate buffer solution pH 7.0.4003700.Mix 82.4mL of a 71.5g/L solution of disodium hydrogen phosphate R with 17.6mL of a 21g/L solution of citric acid R .Phosphate buffer solution pH 7.0R1.4003900.Mix 250.0mL of 0.2M potassium dihydrogen phosphate R and 148.2mL of a 8g/L solution of sodium hydroxide R ,adjust the pH if necessary.Dilute to 1000.0mL with water R .Phosphate buffer solution pH 7.0R2.4004000.Mix 50.0mL of a 136g/L solution of potassium dihydrogenphosphate R with 29.5mL of 1M sodium hydroxide and dilute to 100.0mL with water R .Adjust the pH to 7.0±0.1.Phosphate buffer solution pH 7.0R3.4008600.Dissolve 5g of potassium dihydrogen phosphate R and 11gof dipotassium hydrogen phosphate R in 900mL of water R .Adjust to pH 7.0with dilute phosphoric acid R or dilute sodium hydroxide solution R .Dilute to 1000mL with water R and mix.Phosphate buffer solution pH 7.0R4.4010200.Dissolve 28.4g of anhydrous disodium hydrogen phosphate R and 18.2g of potassium dihydrogen phosphate R in water R and dilute to 500mL with the same solvent.Phosphate buffer solution pH 7.0R5.4011400.Dissolve 28.4g of anhydrous disodium hydrogen phosphate R in 800mL of water R .Adjust the pH using a 30per cent m/m solution of phosphoric acid R and dilute to 1000mL with water R .Tetrabutylammonium buffer solution pH 7.0.4010900.Dissolve 6.16g of ammonium acetate R in a mixture of 15mL of tetrabutylammonium hydroxide solution (400g/L)R and 185mL of water R .Adjust the pH with nitric acid R .Buffered salt solution pH 7.2.4004300.Dissolve in water R 8.0g of sodium chloride R ,0.2g of potassium chloride R ,0.1g of anhydrous calcium chloride R ,0.1g of magnesium chloride R ,3.18g of disodium hydrogen phosphate R and 0.2g of potassium dihydrogen phosphate R and dilute to 1000.0mL with water R .Buffer solution pH 7.2.4004100.To 250.0mL of 0.2M potassium dihydrogen phosphate R add 175.0mL of 0.2M sodium hydroxide .Dilute to 1000.0mL with water R .Adjust the pH if necessary.Phosphate-albumin buffered saline pH 7.2.4004400.Dissolve 10.75g of disodium hydrogen phosphate R ,7.6g of sodium chloride R and 10g of bovine albumin R in water R and dilute to 1000.0mL with the same solvent.Immediately before use adjust the pH using dilute sodium hydroxide solution R or dilute phosphoric acid R .Phosphate-albumin buffered saline pH 7.2R1.4009600.Dissolve 10.75g of disodium hydrogen phosphate R ,7.6g of sodium chloride R and 1g of bovine albumin R in water R and dilute to 1000.0mL with the same solvent.Immediately before use adjust the pH using dilute sodium hydroxide solution Ror dilute phosphoric acid R .Phosphate buffer solution pH 7.2.4004200.Mix 87.0mL of a 71.5g/L solution of disodium hydrogenphosphate R with 13.0mL of a 21g/L solution of citric acid R .Imidazole buffer solution pH 7.3.4004500.Dissolve 3.4g of imidazole R and 5.8g of sodium chloride R in water R ,add 18.6mL of 1M hydrochloric acid and dilute to 1000.0mL with water R .Adjust the pH if necessary.Barbital buffer solution pH 7.4.4004700.Mix 50mL of a solution in water R containing 19.44g/L of sodium acetate R and 29.46g/L of barbital sodium R with 50.5mL of 0.1M hydrochloric acid ,add 20mL of an 85g/L of sodium chloride R and dilute to 250mL with water R .Buffer solution pH 7.4.4004600.Dissolve 0.6g of potassium dihydrogen phosphate R ,6.4g of disodium hydrogen phosphate R and 5.85g of sodium chloride R in water R ,and dilute to 1000.0mL with the same solvent.Adjust the pH if necessary.Phosphate buffered saline pH 7.4.4005000.Dissolve 2.38g of disodium hydrogen phosphate R ,0.19g of potassium dihydrogen phosphate R and 8.0g of sodiumchloride R in water.Dilute to 1000.0mL with the same solvent.Adjust the pH if necessary.Phosphate buffer solution pH 7.4.4004800.Add 250.0mL of 0.2M potassium dihydrogen phosphate R to 393.4mL of 0.1M sodium hydroxide .Tris(hydroxymethyl)aminomethane buffer solution pH 7.4.4012100.Dissolve 30.3g of tris(hydroxymethyl)aminomethane R in approximately 200mL of water R .Add 183mL of 1M hydrochloric acid .Dilute to 500.0mL with water R .Note:the pH is 7.7-7.8at room temperature and 7.4at 37°C.This solution is stable for several months at 4°C.Tris(hydroxymethyl)aminomethane sodium chloride buffer solution pH 7.4.4004900.Dissolve 6.08g of tris(hydroxymethyl)aminomethane R ,8.77g of sodium chloride R in 500mL of distilled water R .Add 10.0g of bovine albumin R .Adjust the pH using hydrochloric acid R .Dilute to 1000.0mL with distilled water R .Tris(hydroxymethyl)aminomethane sodium chloride buffer solution pH 7.4R1.4012200.Dissolve 0.1g of bovine albumin R in a mixture containing 2mL of tris(hydroxymethyl)aminomethane buffer solution pH 7.4R and 50mL of a 5.84mg/mL solution of sodium chloride R .Dilute to 100.0mL with water R .Tris-sodium acetate buffer solution pH 7.4.4012900.Dissolve 6.3g of tris(hydroxymethyl)aminomethane R and 4.9g of anhydrous sodium acetate R in 900mL of water R .Adjust to pH 7.4with sulfuric acid R and dilute to 1000mL with water R .Tris-sodium acetate-sodium chloride buffer solution pH 7.4.4013000.Dissolve 30.0g of tris(hydroxymethyl)aminomethane R ,14.5gof anhydrous sodium acetate R and 14.6g of sodium chloride R in 900mL of water R .Add 0.50g of bovine albumin R .Adjust to pH 7.4with sulfuric acid R and dilute to 1000mL with water R .Borate buffer solution pH 7.5.4005200.Dissolve 2.5g of sodium chloride R ,2.85g of disodium tetraborate R and 10.5g of boric acid R in water R and dilute to 1000.0mL with the same solvent.Adjust the pH if necessary.Storage :at 2°C to 8°C.Buffer (HEPES)solution pH 7.5.4009700.Dissolve 2.38g of 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid R in about 90mL of water R .Adjust thepH to 7.5with sodium hydroxide solution R .Dilute to 100mL with water R .4.1.3.Buffer solutions EUROPEAN PHARMACOPOEIA8.00.05M Phosphate buffer solution pH7.5.4014400. Dissolve0.89g of disodium hydrogen phosphate dihydrate R in about80mL of water R.Adjust to pH7.5with an8.5per cent V/V solution of phosphoric acid R and dilute to100.0mL with water R.0.2M Phosphate buffer solution pH7.5.4005400. Dissolve27.22g of potassium dihydrogen phosphate R in930mL of water R,adjust to pH7.5with a300g/L solution of potassium hydroxide R and dilute to1000.0mL with water R.0.33M Phosphate buffer solution pH7.5.4005300. Dissolve119.31g of disodium hydrogen phosphate R in water R and dilute to1000.0mL with the same solvent(solution A). Dissolve45.36g of potassium dihydrogen phosphate R in water R and dilute to1000.0mL with the same solvent (solution B).Mix85mL of solution A and15mL of solution B. Adjust the pH if necessary.0.05M Tris-hydrochloride buffer solution pH7.5.4005600. Dissolve6.057g of tris(hydroxymethyl)aminomethane R in water R and adjust the pH with hydrochloric acid R.Dilute to 1000.0mL with water R.1M Tris-hydrochloride buffer solution pH7.5.4014500. Dissolve12.11g of tris(hydroxymethyl)aminomethane R in 90mL of water R,adjust to pH7.5with hydrochloric acid R and dilute to100.0mL with water R.Tris(hydroxymethyl)aminomethane buffer solution pH7.5. 4005500.Dissolve7.27g of tris(hydroxymethyl)aminomethane R and 5.27g of sodium chloride R in water R,and adjust the pH if necessary.Dilute to1000.0mL with water R.Sodium citrate buffer solution pH7.8(0.034M sodium citrate,0.101M sodium chloride).4009800.Dissolve10.0g of sodium citrate R and5.90g of sodium chloride R in900mL of water R.Adjust the pH by addition of hydrochloric acid R and dilute to1000mL with water R.0.0015M Borate buffer solution pH8.0.4006000. Dissolve0.572g of disodium tetraborate R and2.94g of calcium chloride R in800mL of water R.Adjust the pH with 1M hydrochloric acid.Dilute to1000.0mL with water R. Buffer solution pH8.0.4005900.To50.0mL of0.2M potassium dihydrogen phosphate R add 46.8mL of0.2M sodium hydroxide.Dilute to200.0mL with water R.Buffer solution pH8.0R1.4010400.Dissolve20g of dipotassium hydrogen phosphate R in900mL of water R.Adjust the pH with phosphoric acid R.Dilute to 1000mL with water R.0.02M Phosphate buffer solution pH8.0.4006100.To50.0mL of0.2M potassium dihydrogen phosphate R add 46.8mL of0.2M sodium hydroxide.Dilute to500.0mL with water R.0.02M Sodium phosphate buffer solution pH8.0.4013700. Dissolve0.31g of sodium dihydrogen phosphate R in70mL of water R and adjust to pH8.0with1M sodium hydroxide,then dilute to100mL with water R.0.1M Phosphate buffer solution pH8.0.4008400. Dissolve0.523g of potassium dihydrogen phosphate R and 16.73g of dipotassium hydrogen phosphate R in water R and dilute to1000.0mL with the same solvent.1M Phosphate buffer solution pH8.0.4007800.Dissolve136.1g of potassium dihydrogen phosphate R in water R,adjust the pH with1M sodium hydroxide.Dilute to 1000.0mL with water R.1M Tris-hydrochloride buffer solution pH8.0.4012700. Dissolve121.1g of tris(hydroxymethyl)aminomethane R and 1.47g of calcium chloride R in900mL of water R.Adjust the pH with hydrochloric acid R and dilute to1000.0mL with water R.Tris-hydrochloride buffer solution pH8.0.4012300. Dissolve1.21g of tris(hydroxymethyl)aminomethane R and 29.4mg of calcium chloride R in water R.Adjust the pH with 1M hydrochloric acid and dilute to100.0mL with water R. Tris-sodium acetate buffer solution pH8.0.4013100. Dissolve6.3g of tris(hydroxymethyl)aminomethane R and 4.9g of anhydrous sodium acetate R in900mL of water R. Adjust to pH8.0with sulfuric acid R and dilute to1000mL with water R.Tris-sodium acetate-sodium chloride buffer solutionpH8.0.4013200.Dissolve30.0g of tris(hydroxymethyl)aminomethane R,14.5g of anhydrous sodium acetate R and14.6g of sodium chloride R in900mL of water R.Add0.50g of bovine albumin R.Adjust to pH8.0with sulfuric acid R and dilute to1000mL with water R.Tris(hydroxymethyl)aminomethane buffer solution pH8.1. 4006200.Dissolve0.294g of calcium chloride R in40mL oftris(hydroxymethyl)aminomethane solution R and adjust the pH with1M hydrochloric acid.Dilute to100.0mL with water R.Tris-glycine buffer solution pH8.3.4006300.Dissolve6.0g of tris(hydroxymethyl)aminomethane R and 28.8g of glycine R in water R and dilute to1000.0mL with the same solvent.Dilute1volume to10volumes with water R immediately before use.Tris-hydrochloride buffer solution pH8.3.4011800. Dissolve9.0g of tris(hydroxymethyl)aminomethane R in2.9L of water R.Adjust the pH with1M hydrochloric acid.Adjust the volume to3L with water R.0.05M Tris-hydrochloride buffer solution pH9.0.4013500. Dissolve0.605g of tris(hydroxymethyl)aminomethane R in water R.Adjust the pH with1M hydrochloric acid and dilute to100.0mL with water R.Barbital buffer solution pH8.4.4006400.Dissolve8.25g of barbital sodium R in water R and dilute to 1000.0mL with the same solvent.Tris-EDTA BSA buffer solution pH8.4.4006500. Dissolve6.1g of tris(hydroxymethyl)aminomethane R,2.8g of sodium edetate R,10.2g of sodium chloride R and10gof bovine albumin R in water R,adjust to pH8.4using1M hydrochloric acid and dilute to1000.0mL with water R.Tris(hydroxymethyl)aminomethane-EDTA buffer solution pH8.4.4006600.Dissolve5.12g of sodium chloride R,3.03g oftris(hydroxymethyl)aminomethane R and1.40g of sodium edetate R in250mL of distilled water R.Adjust the pH to8.4 using hydrochloric acid R.Dilute to500.0mL with distilled water R.Guanidine-tris(hydroxymethyl)aminomethane-EDTA buffer solution pH8.5.4014600.Dissolve1.0g of sodium edetate R,12.1g oftris(hydroxymethyl)aminomethane R and57.0g of guanidine hydrochloride R in35mL of water R.Adjust topH8.5with hydrochloric acid R and dilute to100mL with water R.。

欧洲药典中英文翻译 EP8.0干燥失重

欧洲药典中英文翻译  EP8.0干燥失重

2.2.32. LOSS ON DRYING 干燥失重Loss on drying is the loss of mass expressed as per cent m/m.干燥失重指重量损失,表述为% 重量/重量Method. Place the prescribed quantity of the substance to be examined in a weighing bottle previously dried under the conditions prescribed for the substance to be examined. Dry the substance to constant mass or for the prescribed time by one of the following procedures. Where the drying temperature is indicated by a single value rather than a range, drying is carried out at the prescribed temperature +/- 2?C.方法:将要求数量的待检样品放置于预先干燥的称量瓶中,按要求条件进行干燥,直至样品干至恒重或下述程序指定的时长。

如果干燥温度给定的是一个值而不是一个范围,则在指定温度+/- 2?C进行干燥。

a) “in a desiccator”: the drying is carried out over diphosphorus pentoxide R at atmospheric atmostpheric pressure and at room temperature;“在干燥器中”:指在室温常压下,用五氧化二磷试剂,进行干燥b) “in vacuo”: the drying is carried out over diphosphorus pentoxide R, at a pressure of 1.5 kPa at room temperature;“真空”:在室温下,真空1.5kPa下,用五氧化二磷试剂进行干燥c) “in vacuo within a specified temperature range”: the drying is carried out over diphosphorus pentoxide R, at a pressure of 1.5kPa to 2.5kPa within the temperature range prescribed in the monograph;“在指定温度范围内真空下”:真空1.5kPa至2.5kPa下,各论要求的温度范围内,用五氧化二磷进行干燥d) “in an oven within a specified temperature range”: the drying is carrie d out in an oven within the temperature range prescribed in the monograph;“在烘箱里指定温度下”:在各论要求的温度范围内,用烘箱进行干燥e) “under high vacuum”: the drying is carried out over diphosphorus pentoxide R at a pressure not exceeding 0.1kPa, at the temperature prescribed in the monograph.“在高真空下”:在各论要求的温度下,不超过0.1kPa的真空下用五氧化二磷进行干燥If other conditions are prescribed, the procedure to be used is described in full in the monograph.如果需要采用其它条件,则在各论中应进行详细描述。

欧洲药典8.0版附录2.9.40具体内容

欧洲药典8.0版附录2.9.40具体内容

欧洲药典8.0版附录2.9.40是一项具有重要意义的内容,它包含了关于卫生产品和医药制剂的质量要求和标准。

在这篇文章中,我们将深入探讨这一主题,从基础概念到具体内容,帮助你更好地理解欧洲药典8.0版附录2.9.40。

1. 了解欧洲药典8.0版附录2.9.40欧洲药典是欧洲药典委员会制定的标准规范,旨在保障卫生产品和医药制剂的质量、安全和有效性。

附录2.9.40则是其中的重要内容之一,它详细规定了一系列的质量要求,涵盖了原材料的选择、生产过程的控制、成品的质量检验等方方面面。

这些要求旨在确保药品的质量稳定、安全性高、有效性强。

2. 欧洲药典8.0版附录2.9.40的具体内容欧洲药典8.0版附录2.9.40的具体内容主要包括以下几个方面:- 原材料的要求:包括对原材料的来源、制备、存储和使用的规定,确保原材料的质量稳定和可追溯性。

- 生产过程的控制:包括药品的生产工艺、设备、人员培训等方面的要求,确保生产过程稳定可控、符合GMP要求。

- 药品的质量检验:包括对成品药品的各项质量指标和检测方法的规定,确保药品符合质量标准。

3. 个人观点和理解欧洲药典8.0版附录2.9.40的具体内容凸显了对药品质量和安全的高标准要求,这种规范的制定对保障患者用药安全、促进药品质量提升有着重要的意义。

而且,这种规范也对制药企业的生产经营提出了更高的要求,能够推动行业向着更加规范、科学的方向发展。

总结回顾通过本文的阐述,相信你对欧洲药典8.0版附录2.9.40有了更深入的了解。

这一规范的制定和实施,促进了药品质量的提升、促进了医药行业的良性发展,对患者和企业来说都具有重要意义。

希望你能在日常工作和学习中,更加关注和重视这一规范,促进药品质量和安全的保障。

4. 药品质量和安全的重要性药品质量和安全对于患者的健康和生命安全具有重要的意义。

优质的药品能够有效治疗疾病,保障患者的健康。

然而,如果药品质量不达标或者存在安全隐患,可能会导致患者用药失败或者出现严重的副作用,危及患者的生命安全。

欧洲药典EP8.0-2.6.1无菌检验-sterility中英文翻译

欧洲药典EP8.0-2.6.1无菌检验-sterility中英文翻译

欧洲药典EP8.0-2.6.1无菌检验-sterility中英文翻译2.6.1. STERILITY2.6.1 无菌检查法The test is applied to substances, preparations or articles which, accordingto the Pharmacopoeia, are required to be sterile. However, a satisfactory result only indicates that no contaminating micro-organism has been found in the sample examined in the conditions of the test.本检查方法适用于按照药典要求应当无菌的原料、制剂或其他物质。

但是,如果按照本无菌检查法的结果符合要求,仅表明在该检查条件下未发现微生物污染。

PRECAUTIONS AGAINST MICROBIAL CONTAMINATION微生物污染防范The test for sterility is carried out under aseptic conditions. In order to achieve such conditions, the test environment has to be adapted to the way in which the sterility test is performed. The precautions taken to avoid contamination are such that they do not affect any micro-organisms which are to be revealed in the test. The working conditions in which the tests are performed are monitored regularly by appropriate sampling of the working area and by carrying out appropriate controls.无菌检测试验应在无菌的条件下进行。

Alfacalcidol-欧洲药典EP8.0

Alfacalcidol-欧洲药典EP8.0

Alfacalcidol EUROPEAN PHARMACOPOEIA8.0Limits :–impurities A,B :for each impurity,not more than the area of the principal peak in the chromatogram obtained with reference solution (a)(0.5per cent)and not more than one of the peaks has an area greater than the area of the principal peak in the chromatogram obtained with reference solution (b)(0.2per cent);–total :not more than twice the area of the principal peak in the chromatogram obtained with reference solution (a)(1per cent);–disregard limit :the area of the principal peak in the chromatogram obtained with reference solution (c)(0.05per cent).Water (2.5.12):maximum 5.0per cent,determined on 0.500g.Sulfated ash (2.4.14):maximum 0.1per cent,determined on 1.0g.ASSAYDissolve 0.300g by stirring in 70mL of acetic anhydride R for 1min.Titrate with 0.1M perchloric acid until the colour changes from violet-blue to greenish-blue,using 0.1mL of crystal violet solution R as indicator.1mL of 0.1M perchloric acid is equivalent to 36.9mg of C 44H 50Cl 2N 4O 2.STORAGEIn an airtight container under nitrogen,protected from light,at a temperature of 2°C to 8°C.IMPURITIESSpecified impurities:A,B.A.(1R ,3a S ,9R ,9a R ,10R ,11a S ,12R ,14a S ,19a S ,20R ,-20a R ,20b S ,21R ,22a S )-1,12-bis(prop-2-enyl)-2,3,9a,11,11a,13,14,19a,20a,21,22,22a-dodecahydro-10H ,20b H -1,23:12,27-dimethano-9,10:20,21-bis(epoxyprop[2]eno)-9H ,20H -[1,5]diazocino[1,2,3-lm :5,6,7-l ′m ′]dipyrrolo[2′,3′-d :2′′,3′′:d ′]dicarbazolediium dichloride (4,4′-diallylcaracurin Vdichloride),B.(4b S ,7R ,7a S ,8a R ,13R ,13a R ,13b S )-13-hydroxy-7-(prop-2-enyl)-5,6,7a,8,8a,11,13,13a,13b,14-decahydro-7,9-methano-7H -oxepino[3,4-a ]pyrrolo[2,3-d ]carbazolium chloride ((4R ,17R )-4-allyl-17,18-epoxy-17-hydroxy-19,20-didehydrocuranium chloride).01/2014:1286ALFACALCIDOLAlfacalcidolumC 27H 44O 2M r 400.6[41294-56-8]DEFINITION(5Z ,7E )-9,10-Secocholesta-5,7,10(19)-triene-1α,3β-diol.Content :97.0per cent to 102.0per cent.A reversible isomerisation to pre-alfacalcidol takes place in solution,depending on temperature and time.The activity is due to both compounds (see Assay).CHARACTERSAppearance :white or almost white crystals.Solubility :practically insoluble in water,freely soluble in ethanol (96per cent),soluble in fatty oils.It is sensitive to air,heat and light.IDENTIFICATIONA.Infrared absorption spectrophotometry (2.2.24).Comparison :Ph.Eur.reference spectrum of alfacalcidol .B.Examine the chromatograms obtained in the test for related substances.Results :the principal peak in the chromatogram obtained with the test solution is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (a).TESTSRelated substances .Liquid chromatography (2.2.29):use the normalisation procedure.Carry out the test as rapidly as possible,avoiding exposure to light and air.Test solution.Dissolve 1.0mg of the substance to be examined without heating in 10.0mL of the mobile phase.Reference solution (a).Dissolve 1.0mg of alfacalcidol CRS without heating in 10.0mL of the mobile phase.Reference solution (b).Dilute 1.0mL of reference solution (a)to 100.0mL with the mobile phase.Dilute 1.0mL of this solution to 20.0mL with the mobile phase.Reference solution (c).In order to prepare pre-alfacalcidol in situ ,dissolve the contents of a vial of alfacalcidol for system suitability CRS (containing impurities A and B)in 25mL of the mobile phase,heat in a water-bath at 80°C under a reflux condenser for 2h and cool.Column :–size :l =0.25m,Ø=4.6mm;–stationary phase :end-capped octadecylsilyl silica gel for chromatography R (5μm).Mobile phase :ammonia R ,water R ,acetonitrile R (1:200:800V/V/V ).Flow rate :2.6mL/min.Detection :spectrophotometer at 265nm.Injection :100μL of the test solution and reference solutions (b)and (c).1498See the information section on general monographs (cover pages)EUROPEAN PHARMACOPOEIA 8.0AlfadexRun time :twice the retention time of alfacalcidol.Identification of impurities :use the chromatogramsupplied with alfacalcidol for system suitability CRS and the chromatogram obtained with reference solution (c)to identify the peaks due to impurities A and B.Relative retention with reference to alfacalcidol (retention time =about 21min):pre-alfacalcidol =about 0.88;impurity A =about 0.93;impurity B =about 1.1.System suitability :reference solution (c):–resolution :minimum 1.5between the peaks due to pre-alfacalcidol and impurity A and minimum 1.5between the peaks due to impurity A and alfacalcidol.Limits :–impurities A,B :for each impurity,maximum 0.5per cent;–unspecified impurities :for each impurity,maximum 0.10per cent;–total :maximum 1.0per cent;–disregard limit :the area of the principal peak in the chromatogram obtained with reference solution (b)(0.05per cent);disregard the peak due to pre-alfacalcidol.ASSAYLiquid chromatography (2.2.29)as described in the test for related substances with the following modifications.Injection :test solution and reference solutions (a)and (c).System suitability :reference solution (c):–repeatability :maximum relative standard deviation of 1per cent for the peak due to alfacalcidol after 6injections.Calculate the percentage content of C 27H 44O 2taking into account the assigned content of alfacalcidol CRS and,if necessary,the peak due to pre-alfacalcidol.STORAGEUnder nitrogen,in an airtight container,protected from light,at a temperature of 2°C to 8°C.The contents of an opened container are to be used immediately.IMPURITIESSpecified impurities:A,B .Other detectable impurities (the following substances would,if present at a sufficient level,be detected by one or other of the tests in the monograph.They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034).It is therefore not necessary to identify these impurities for demonstration of compliance.See also 5.10.Control of impurities in substances for pharmaceutical use ):C.A.(5E ,7E )-9,10-secocholesta-5,7,10(19)-triene-1α,3β-diol (trans-alfacalcidol), B.(5Z ,7E )-9,10-secocholesta-5,7,10(19)-triene-1β,3β-diol(1β-calcidol),C.6ξ-[(3S ,5R )-3,5-dihydroxy-2-methylcyclohex-1-en-1-yl]-2-phenyl-2,5,10-triaza-4,19-dinor-9ξ-cholest-7-ene-1,3-dione.01/2012:1487ALFADEXAlfadexum[C 6H 10O 5]6M r 973[10016-20-3]DEFINITIONCyclohexakis-(1→4)-(α-D -glucopyranosyl)(cyclomaltohexaose or α-cyclodextrin).Content :97.0per cent to 102.0per cent (dried substance).CHARACTERSAppearance :white or almost white,amorphous or crystalline powder.Solubility :freely soluble in water and in propylene glycol,practically insoluble in anhydrous ethanol and in methylene chloride.IDENTIFICATIONA.Specific optical rotation (see Tests).B.Examine the chromatograms obtained in the assay.Results :the principal peak in the chromatogram obtained with test solution (b)is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (c).C.Dissolve 0.2g in 2mL of iodine solution R4by warming on a water-bath,and allow to stand at room temperature;a yellowish-brown precipitate is formed.General Notices (1)apply to all monographs and other texts1499。

欧洲药典8.0-凡例双语版

欧洲药典8.0-凡例双语版

1 GENERAL NOTICES凡例1.1 GENERAL STATEMENTS概述The General Notices apply to all monographs and other texts of the EuropeanPharmacopoeia.凡例的内容适用于各论和欧洲药典中的其它章节。

The official texts of the European Pharmacopoeia are published in English andFrench. Translations in other languages may be prepared by the signatoryStates of the European Pharmacopoeia Convention. In case of doubt or dispute,the English and French versions are alone authoritative.欧洲药典以英语和法语形式发行,欧洲药典委员会的签署国可将药典内容译成其它语言,但若发生争议,应以英语和法语版为权威。

In the texts of the European Pharmacopoeia, the word ‘Pharmacopoeia’ without qualification means the European Pharmacopoeia. The official abbreviation Ph.Eur. may be used to indicate the European Pharmacopoeia.在欧洲药典中,如无特殊规定,“药典”是指欧洲药典,官方缩写 Ph. Eur.也指欧洲药典。

The use of the title or the subtitle of a monograph implies that the articlecomplies with the requirements of the relevant monograph. Such references tomonographs in the texts of the Pharmacopoeia are shown using themonograph title and reference number in italics.文章中如果引用了各论中的标题和副标题意味着文章内容符合相关各论的要求。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

1 GENERAL NOTICES凡例1.1 GENERAL STATEMENTS概述The General Notices apply to all monographs and other texts of the European Pharmacopoeia.凡例的内容适用于各论和欧洲药典中的其它章节。

The official texts of the European Pharmacopoeia are published in English and French. Translations in other languages may be prepared by the signatoryStates of the European Pharmacopoeia Convention. In case of doubt or dispute, the English and French versions are alone authoritative.欧洲药典以英语和法语形式发行,欧洲药典委员会的签署国可将药典内容译成其它语言,但若发生争议,应以英语和法语版为权威。

In the texts of the European Pharmacopoeia, the word ‘Pharmacopoeia’ without qualification means the European Pharmacopoeia. The official abbreviation Ph.Eur. may be used to indicate the European Pharmacopoeia.在欧洲药典中,如无特殊规定,“药典”是指欧洲药典,官方缩写 Ph. Eur.也指欧洲药典。

The use of the title or the subtitle of a monograph implies that the articlecomplies with the requirements of the relevant monograph. Such references to monographs in the texts of the Pharmacopoeia are shown using themonograph title and reference number in italics.文章中如果引用了各论中的标题和副标题意味着文章内容符合相关各论的要求。

文章参考药典中各论内容时,以斜体的各论题目或相关数字表示。

A preparation must comply throughout its period of validity; a distinct period ofvalidity and/or specifications for opened or broached containers may bedecided by the competent authority. The subject of any other monograph must comply throughout its period of use. The period of validity that is assigned to any given article and the time from which that period is to be calculated aredecided by the competent authority in light of experimental results of stability studies.制剂在有效期内必须性质稳定,明确的有效期或说明书应由权力机构批准。

任何各论的物质也必须服从其使用期限。

任何药品的有效期和有效期的计算由权力机构经稳定性研究的试验结果决定。

Unless otherwise indicated in the General Notices or in the monographs,statements in monographs constitute mandatory requirements. Generalchapters become mandatory when referred to in a monograph, unless suchreference is made in a way that indicates that it is not the intention to make the text referred to mandatory but rather to cite it for information.除凡例和各论中另有说明,各论中的说明为强制要求;除了特定的引用信息,如果各论引用总论中内容时,该总论要求为法定要求。

The active substances, excipients, pharmaceutical preparations and other articles described in the monographs are intended for human and veterinary use (unless explicitly restricted to one of these uses). An article is not of Pharmacopoeia quality unless it complies with all the requirements stated in the monograph. This does not imply that performance of all the tests in a monograph is necessarily a prerequisite for a manufacturer in assessing compliance with the Pharmacopoeia before release of a product. The manufacturer may obtain assurance that a product is of Pharmacopoeia quality from data derived, for example, from validation studies of the manufacturing process and from in-process controls. Parametric release in circumstances deemed appropriate by the competent authority is thus not precluded by the need to comply with the Pharmacopoeia.各论中描述的活性物质,辅料,药物制剂和其它项目都是人用和兽用的(除非明确限制不可使用)。

药品项目必须符合各论的要求,否则不符合药典质量。

但并不要求产品放行前,生产商要做各论中的每项试验以满足药典要求。

生产商可通过原始数据,例如生产过程验证,和中间体控制,确保药品是否符合药典要求。

公布的环境参数,权力机构可适当采信,但不排除故意满足药典要求的可能。

The tests and assays described are the official methods upon which the standards of the Pharmacopoeia are based. With the agreement of the competent authority, alternative methods of analysis may be used for control purposes, provided that the methods used enable an unequivocal decision to be made as to whether compliance with the standards of the monographs would be achieved if the official methods were used. In the event of doubt or dispute, the methods of analysis of the Pharmacopoeia are alone authoritative. 检测和试验方法应基于药典标准的官方方法。

经权利机构允许可采用其它替代的分析方法以达到控制目的,并证明该方法是否能达到各论各标准。

若出现争论或异议,应以药典方法为准。

Certain materials that are the subject of a pharmacopoeial monograph may exist in different grades suitable for different purposes. Unless otherwise indicated in the monograph, the requirements apply to all grades of the material. In some monographs, particularly those on excipients, a list offunctionality-related characteristics that are relevant to the use of the substance may be appended to the monograph for information. Test methods for determination of one or more of these characteristics may be given, also for information.药典各论中的某些物质有多个等级可满足各种需要,除各论中另有说明,要求适用于各等级。

在一些各论中,特别是辅料,一系列相关的功能特性都有介绍,其中给出了一些特性的检测方法。

Quality systems. The quality standards represented by monographs are valid only where the articles in question are produced within the framework of a suitable quality system.质量体系:在适宜的质量体系架构下,产生有疑问的项目时,应以各论中的质量标准为法定标准。

相关文档
最新文档